Photodynamic Therapy for Circumscribed Choroidal Hemangioma in 79 Consecutive Patients

Double Fluence Photodynamic Therapy for the Treatment of Circumscribed Choroidal Hemangioma

“…The first two cases of CCH treated with PDT were described in 2000 by Barbazetto and Schmidt-Erfurth, 8 and since then numerous reports have appeared in the literature. [11][12][13][14][15][16][17][18][19][20][21][22][23][24] In 2002, Schmidt-Erfurth et al 11 published a case series of 15 patients with a success rate of 100% in visual outcome, tumor regression, and fluid reabsorption at 12 months from PDT treatment, but with a retreatment rate of 80%. In 2003, Jurklies et al 21 reported a 100% rate of tumor regression in 19 eyes, a 95% of BCVA improvement and fluid reabsorption, and a 63,2% of cases was retreated.…”

“…10 Half duration (41 seconds) was also reported to treat tumors underlying the fovea to reduce possible risk of central visual loss. 20 Some CCHs were treated with overlapping or no overlapping spots to cover the whole tumor area, whereas in other cases, a single spot was used for the most prominent part of the tumor. 10,11,20 Regarding these different PDT approaches, Boixadera et al 19 in 2009, published a series of 32 patients with CCH treated with standard protocol, in which he reported a 93% of reabsorption of SRF and an improvement of BCVA in 96.5% of patients after 12 months, but with a retreatment rate of 17.2%.…”

“…10 Half duration (41 seconds) was also reported to treat tumors underlying the fovea to reduce possible risk of central visual loss. 20 Some CCHs were treated with overlapping or no overlapping spots to cover the whole tumor area, whereas in other cases, a single spot was used for the most prominent part of the tumor. 10,11,20…”

Photodynamic Therapy in Ocular Oncology

“…[17] In a recent study by Di Nicola et al, investigating the predictive factors of visual outcome in 79 patients with CCH treated with PDT, the authors found correlations between good final visual outcome (≥20/40) and good baseline visual acuity, smaller tumor size, lack of CME, and lack of treatment prior to PDT. [18] With regards to the treatment parameters, double-dose PDT (12 mg/m 2 ) provided better tumor regression with similar resorption of SRF compared with standard-dose PDT (6 mg/ m 2 ). Single-spot PDT was as effective and safe as overlapping-spot PDT (two to three spots).…”

From molecules to nanovectors: Current state of the art and applications of photosensitizers in photodynamic therapy

“…Besides, these are pure compounds, quickly eliminated by tissues, thus limiting the period of skin photosensitization (Nowak-Stepniowska et al, 2013). Currently, the second generation photosensitizers group includes 5-aminolevulinic acid (Effala ® , Ameluz ®, , Gliolan ® , Alacare ® ) (Fukuhara et al, 2020), methyl-aminolevulinate (Metvix ® , Metvixia ® ), mesotetrahydroxyphenylchlorin (Foscan ® ) (Posadzki and Car, 2018), benzoporphyne derivatives (Visudyne ® ) (Di Nicola et al, 2020), rostaporfin (Purlytin ® ) (Hunt, 2002), padeliporfin (Tookad ® ) (Fukuhara et al, 2020), mono-L-aspartylchlorine e6 (Laserphyrin ® , Aptocine ® ) (Aizawa et al, 1987), phthalocyanines (Rak et al, 2019), lutetium texaphyrin (Lutex ® , Lutrin ® ) (Young et al, 1996), lutetium motexafin (Antrin ® ) (Chen et al, 2001), gadolinium motexafin (Xcytrin ® ) (Evens, 2004), methylene blue (Dos Santos et al, 2017) and rose bengal (Dini et al, 2010).…”